AB-Aware

Pai, Suhit; Singh, Newton; Singh, Virendra

doi:10.1145/3194554.3194573

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of these methods utilized measure and quantify this drug-bound iron species, DBI. 28,[32][33][34] Therefore, very little is known about the direct pharmacokinetics of DBI. The development of a direct measure of the drug in plasma (DBI) would be a major advance.…”

Section: Introductionmentioning

confidence: 99%

Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography–Inductively Coupled Plasma–Mass Spectrometric Approach

et al. 2019

View full text Add to dashboard Cite

Nanomedicines are nanoparticle-based therapeutic or diagnostic agents designed for targeted delivery or enhanced stability. Nanotechnology has been successfully employed to develop various drug formulations with improved pharmacokinetic characteristics, and current research efforts are focused on the development of new innovator and generic nanomedicines. Nanomedicines, which are often denoted as complex or nonbiological complex drugs, have inherently different physicochemical and pharmacokinetic properties than conventional small molecule drugs. The tools necessary to fully evaluate nanomedicines in clinical settings are limited, which can hamper their development. One of the most successful families of nanomedicines are iron-carbohydrate nanoparticles, which are administered intravenously (IV) to treat iron-deficiency anemia. In the U.S., the FDA has approved six distinct iron-carbohydrate nanoparticles but only one generic version (sodium ferric gluconate for Ferrlecit). There is significant interest in approving additional generic iron-carbohydrate drugs; however, the lack of a direct method to monitor the fate of the iron nanoparticles in clinical samples has impeded this approval. Herein we report a novel liquid *

show abstract

Section: Introductionmentioning

confidence: 99%

Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography–Inductively Coupled Plasma–Mass Spectrometric Approach

et al. 2019

View full text Add to dashboard Cite

show abstract

A Survey of Techniques for Reducing Interference in Real-Time Applications on Multicore Platforms

et al. 2022

View full text Add to dashboard Cite

This survey reviews the scientific literature on techniques for reducing interference in real-time multicore systems, focusing on the approaches proposed between 2015 and 2020. It also presents proposals that use interference reduction techniques without considering the predictability issue. The survey highlights interference sources and categorizes proposals from the perspective of the shared resource. It covers techniques for reducing contentions in main memory, cache memory, a memory bus, and the integration of interference effects into schedulability analysis. Every section contains an overview of each proposal and an assessment of its advantages and disadvantages.INDEX TERMS Real-time systems, architecture, multicore, timing analysis, schedulability analysis, WCET, co-runner interference.

show abstract

AB-Aware

Cited by 2 publications

References 13 publications

Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography–Inductively Coupled Plasma–Mass Spectrometric Approach

Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography–Inductively Coupled Plasma–Mass Spectrometric Approach

A Survey of Techniques for Reducing Interference in Real-Time Applications on Multicore Platforms

Contact Info

Product

Resources

About